These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 25020100)

  • 1. Pretransplantation therapy with hypomethylating agents in patients with myelodysplastic syndromes receiving reduced-intensity conditioning regimens.
    Della Porta MG; Alessandrino EP
    Biol Blood Marrow Transplant; 2014 Sep; 20(9):1260-1. PubMed ID: 25020100
    [No Abstract]   [Full Text] [Related]  

  • 2. Upfront allogeneic stem cell transplantation after reduced-intensity/nonmyeloablative conditioning for patients with myelodysplastic syndrome: a study by the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
    Damaj G; Mohty M; Robin M; Michallet M; Chevallier P; Beguin Y; Nguyen S; Bories P; Blaise D; Maillard N; Rubio MT; Fegueux N; Cornillon J; Clavert A; Huynh A; Adès L; Thiébaut-Bertrand A; Hermine O; Vigouroux S; Fenaux P; Duhamel A; Yakoub-Agha I
    Biol Blood Marrow Transplant; 2014 Sep; 20(9):1349-55. PubMed ID: 24838178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transplants in myelodysplastic syndromes.
    Wetzko K; Platzbecker U
    Hematol Oncol Clin North Am; 2014 Dec; 28(6):1011-22. PubMed ID: 25459176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents.
    Festuccia M; Baker K; Gooley TA; Sandmaier BM; Deeg HJ; Scott BL
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1509-1514. PubMed ID: 28600031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can hypomethylating agents provide a platform for curative therapy in myelodysplastic syndromes?
    Steensma DP
    Best Pract Res Clin Haematol; 2012 Dec; 25(4):443-51. PubMed ID: 23200541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transplantation for MDS in the elderly: more evidence, or more bias?
    Cutler C
    Biol Blood Marrow Transplant; 2012 Sep; 18(9):1320-1. PubMed ID: 22750646
    [No Abstract]   [Full Text] [Related]  

  • 7. Which Patients Should Undergo Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes, and When Should We Do It?
    Oran B
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S43-9. PubMed ID: 26297277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS.
    Gerds AT; Gooley TA; Estey EH; Appelbaum FR; Deeg HJ; Scott BL
    Biol Blood Marrow Transplant; 2012 Aug; 18(8):1211-8. PubMed ID: 22252125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pretransplantation 5-azacitidine in high-risk myelodysplastic syndrome.
    Nishihori T; Perkins J; Mishra A; Komrokji R; Kim J; Kharfan-Dabaja MA; Perez L; Lancet J; Fernandez H; List A; Anasetti C; Field T
    Biol Blood Marrow Transplant; 2014 Jun; 20(6):776-80. PubMed ID: 24534108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of MDS].
    Usuki K
    Rinsho Ketsueki; 2014 Oct; 55(10):1882-92. PubMed ID: 25297752
    [No Abstract]   [Full Text] [Related]  

  • 11. Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and acute myelogenous leukemia.
    Valcárcel D; Martino R
    Curr Opin Oncol; 2007 Nov; 19(6):660-6. PubMed ID: 17906468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemia.
    Flotho C; Sommer S; Lübbert M
    Semin Cancer Biol; 2018 Aug; 51():68-79. PubMed ID: 29129488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular alterations monitoring in myelodysplastic patients receiving an allogeneic hematopoietic stem cell transplantation after a reduced-intensity conditioning regimen.
    Robin M; Nibourel O; Tournaire M; Michonneau D; Preudhomme C; Verbanck M; Xhaard A; Adès L; Sicre de Fontbrune F; Sébert M; Fenaux P; Socié G; Peffault de Latour R; Curis E
    Bone Marrow Transplant; 2024 Sep; 59(9):1309-1312. PubMed ID: 38783124
    [No Abstract]   [Full Text] [Related]  

  • 14. CD34+ cell dose in allogeneic transplantation: weight considerations.
    Basquiera AL; Abichaín P; Damonte JC; García JJ
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):196. PubMed ID: 25270957
    [No Abstract]   [Full Text] [Related]  

  • 15. Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies.
    Damaj G; Duhamel A; Robin M; Beguin Y; Michallet M; Mohty M; Vigouroux S; Bories P; Garnier A; El Cheikh J; Bulabois CE; Huynh A; Bay JO; Legrand F; Deconinck E; Fegueux N; Clement L; Dauriac C; Maillard N; Cornillon J; Ades L; Guillerm G; Schmidt-Tanguy A; Marjanovic Z; Park S; Rubio MT; Marolleau JP; Garnier F; Fenaux I; Yakoub-Agha I
    J Clin Oncol; 2012 Dec; 30(36):4533-40. PubMed ID: 23109707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addition of 10-Day Decitabine to Fludarabine/Total Body Irradiation Conditioning is Feasible and Induces Tumor-Associated Antigen-Specific T Cell Responses.
    Cruijsen M; Hobo W; van der Velden WJFM; Bremmers MEJ; Woestenenk R; Bär B; Falkenburg JHF; Kester M; Schaap NPM; Jansen J; Blijlevens NNM; Dolstra H; Huls G
    Biol Blood Marrow Transplant; 2016 Jun; 22(6):1000-1008. PubMed ID: 26860635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful allogeneic stem-cell transplantation in a patient with myelodysplastic syndrome with hemodialysis-dependent end-stage renal disease.
    Choi HS; Kim SY; Lee JH; Yoon SY; Cho YH; Lee HG
    Transplantation; 2011 Sep; 92(6):e28-9. PubMed ID: 21909016
    [No Abstract]   [Full Text] [Related]  

  • 18. Should cytoreductive treatment be performed before transplantation in patients with high-risk myelodysplastic syndrome?
    Alessandrino EP; Della Porta MG; Pascutto C; Bacigalupo A; Rambaldi A
    J Clin Oncol; 2013 Jul; 31(21):2761-2. PubMed ID: 23775971
    [No Abstract]   [Full Text] [Related]  

  • 19. Multicenter biologic assignment trial comparing reduced-intensity allogeneic hematopoietic cell transplant to hypomethylating therapy or best supportive care in patients aged 50 to 75 with intermediate-2 and high-risk myelodysplastic syndrome: Blood and Marrow Transplant Clinical Trials Network #1102 study rationale, design, and methods.
    Saber W; Le Rademacher J; Sekeres M; Logan B; Lewis M; Mendizabal A; Leifer E; Appelbaum FR; Horowitz MM; Nakamura R; Cutler CS
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1566-72. PubMed ID: 24972249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced-intensity and nonmyeloablative conditioning regimens.
    Foss F; van Besien K
    Cancer Treat Res; 2009; 144():209-32. PubMed ID: 19779868
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.